Results 101 to 110 of about 284 (126)

Population pharmacokinetics of the dual endothelin receptor antagonist aprocitentan in subjects with or without essential or resistant hypertension

Journal of Pharmacokinetics and Pharmacodynamics
Aprocitentan is a novel, potent, dual endothelin receptor antagonist that recently demonstrated efficacy in the treatment of difficult-to-treat (resistant) hypertension. The aim of this study was to develop a population pharmacokinetic (PK) model describing aprocitentan plasma concentration over time, to investigate relationships between subject ...
Janneke M Brussee, Patricia N Sidharta, Jasper Dingemanse   +2 more
exaly   +3 more sources

Multiple‐Dose Pharmacokinetics, Safety, and Tolerability of Aprocitentan, a Dual Endothelin Receptor Antagonist, in Healthy Japanese and Caucasian Subjects

Clinical Pharmacology in Drug Development, 2021
Jasper Dingemanse, Patricia N Sidharta
exaly   +2 more sources

Randomized Dose-Response Study of the New Dual Endothelin Receptor Antagonist Aprocitentan in Hypertension

Hypertension, 2020
Bruno Flamion, J Menard
exaly   +2 more sources

Absorption, Distribution, Metabolism, and Excretion of Aprocitentan, a Dual Endothelin Receptor Antagonist, in Humans

Current Drug Metabolism, 2021
Background: Aprocitentan is an orally active, dual endothelin receptor antagonist that may offer a new therapeutic option for the treatment of difficult-to-control hypertension. Objective: To investigate safety, tolerability, mass balance, absorption, distribution, metabolism, and excretion of aprocitentan.
Patricia N. Sidharta, Hartmut Fischer, Jasper Dingemanse   +2 more
openaire   +2 more sources

Aprocitentan, an endothelin receptor antagonist for resistant hypertension

JAAPA
ABSTRACT Resistant hypertension (RH) is defined as blood pressure (BP) that remains uncontrolled with use of three or more antihypertensive medications or BP that is controlled with use of four antihypertensive medications.
Emily, Weidman-Evans, Lindsay, Ferrington   +1 more
openaire   +2 more sources

A New Drug for Resistant Hypertension: Aprocitentan

Current Hypertension Reviews
Abstract: Resistant hypertension (RH) is defined as uncontrolled blood pressure (BP) despite the use of three or more antihypertensive agents of different pharmacological classes. The treat-ment of resistant hypertension remains a challenge, as it is associated with a heightened risk of cardiovascular events ...
Jaspreet Kaur Sidhu, Deepti Chopra, Abhinav Goyal, Yangshen Lhamo   +3 more
openaire   +2 more sources

Aprocitentan (Tryvio) for Hypertension

The Medical Letter on Drugs and Therapeutics
The FDA has approved the dual endothelin receptor antagonist aprocitentan (Tryvio – Idorsia) for use in combination with other antihypertensive drugs to treat hypertension in adults whose blood pressure is not adequately controlled on other drugs. Three other dual endothelin receptor antagonists, ambrisentan (Volibris, and generics), bosentan (Tracleer,
openaire   +2 more sources

Aprocitentan: The First Endothelin Receptor Antagonist for Resistant Hypertension

American Journal of Therapeutics
Background: Hypertension is a serious health problem, and resistant hypertension occurs when blood pressure (BP) is uncontrolled despite at least 3 optimal-dosed agents of different pharmacologic classes. Aprocitentan is a novel pharmacological agent approved in early 2024 for treatment of hypertension, in ...
Timothy Nguyen, Hui Lin, Diana Tint, Lorena Dima, Zhe (Amy) Wang   +4 more
openaire   +2 more sources

Aprocitentan: A New Frontier in Hypertension Management

International Journal of Pharmaceutical Science Invention
Aprocitentant is a novel antagonist of the neurokinin-1 (NK1) receptor, primarily developed for the treatment of chemotherapy-induced nausea and vomiting (CINV). This review provides a comprehensive analysis of its pharmacokinetics, clinical trial outcomes, and overall efficacy.
Rutuja.S.Dagale Rutuja.S.Dagale, Sneha.B.Sable Sneha.B.Sable, Miss Sonali bhangare Miss Sonali bhangare, Dr. Pallavi Phalke Dr. Pallavi Phalke   +3 more
openaire   +1 more source

BLOOD PRESSURE CONTROL WITH APROCITENTAN IN RESISTANT HYPERTENSION

Journal of Hypertension
Objective: The results of the phase 3 PRECISON study demonstrated that in patients with resistant hypertension, aprocitentan in addition to a fixed-dose combination of amlodipine, valsartan, hydrochlorothiazide was well tolerated and superior to placebo in lowering blood pressure at week 4 with a sustained effect at week 40 ...
Krzysztof Narkiewicz, Parisa Danaietash, Grzegorz Kania, Ilkka Kantola, Fernando Martinez-garcia, Mouna Sassi-sayadi, Markus P Schlaich, Nicole Toursarkissian, Ji -GUANG Wang, Michael A Weber, Alberto Gimona   +10 more
openaire   +1 more source